Professor Chambers is Director of the Centre for Inflammation and Tissue Repair and is also Vice-Dean (Enterprise) for the UCL Faculty of Medical Sciences. Her research programme is focused on identifying the key cellular mechanisms and signalling pathways involved in driving lung injury, inflammation and fibrosis, with a particular emphasis on the role of the proteinase-activated receptors (PARs) and the TGF-β signalling axis. This research programme is based within the clinical settings of acute respiratory distress syndrome, pulmonary fibrosis and airway remodelling and integrates fundamental studies in cell, tissue and disease model systems through to translational studies in humans.  Professor Chambers’ group encompasses an active and dynamic mix of scientists, clinician scientists and PhD students and is supported by grants obtained from major funding agencies, including The Medical Research Council, The British Lung Foundation, The Wellcome Trust and The Rosetrees Trust.

Professor Chambers has a keen interest in Enterprise and also directs a discovery biology group at UCL as part of a major academic-industry alliance with GlaxoSmithKline (GSK) in the area of fibrosis. The industry partnership lead for this programme is Dr Paul Mercer, a senior Research Associate with extensive expertise in novel drug target identification and validation. Professor Chambers has also has recently established a small research team in order to prosecute novel targets in the context of neutrophilic inflammation at the Stevenage Bioscience Catalyst (SBC).  The SBC innovation lead for this initiative is Dr Andrew Williams, who has a longstanding track-record in lung inflammation and immunology.